세계의 제한핵산내부가수분해효소 시장 : 규모 조사 - 최종 사용자별, 용도별, 지역별 예측(2022-2032년)

Global Restriction Endonucleases Market is valued approximately at USD 401.1 million in 2023 and is anticipated to grow with a healthy growth rate of more than 6.60% over the forecast period 2024-2032. Restriction endonucleases, commonly referred to as restriction enzymes, possess the unique capability to cleave DNA molecules at precise locations. These enzymes play a crucial role in molecular biology and genetic engineering by enabling scientists to precisely cut DNA molecules. This precision in cutting DNA at specific sequences is harnessed in various techniques such as DNA cloning, gene mapping, and genetic manipulation. Restriction endonucleases are essential components of DNA recombinant technology, utilized to scan DNA for specific sequences typically consisting of six or four nucleotides. Upon identifying these target DNA sequences, the restriction endonucleases initiate a process known as enzyme digestion, cleaving the DNA strand precisely at these designated locations. . The growing advancements in Next-Generation Sequencing (NGS) is a significant trend in the global restriction endonucleases market over the forecast period 2024-2032.The integration of NGS techniques in molecular biology and genomics research is fueling the demand for high-quality restriction endonucleases for sample preparation and analysis. .

The growth of the restriction endonucleases market is driven by their expanding use in diverse applications like in vivo gene editing, epigenetic modifications, and DNA library construction. Moreover, increased investment in R&D for molecular biology procedures and techniques contributes significantly to market expansion. Ongoing advancements in enzyme engineering and biotechnology contribute to the development of more efficient and specialized restriction endonucleases. Improved enzyme properties, such as higher specificity and enhanced stability, drive adoption in research and diagnostic applications. Moreover, increased investments and governmental funding in genetic engineering are poised to drive market expansion. For example, in December 2023, Tome secured USD 213.0 million in Series A and B funding from investors such as Andreessen Horowitz Bio + Health, ARCH Venture Partners, GV, Longwood Fund, Polaris Partners, Bruker Corporation, FUJIFILM Corporation, and Alexandria Venture Investments. These funds will bolster Tome's endeavors in developing and commercializing programmable genomic integration (PGI) technology, licensed from the Massachusetts Institute of Technology (MIT). Consequently, this funding and the escalating research initiatives in genetic engineering utilizing restriction endonucleases for genetic disease therapies are forecasted to propel segment growth throughout the projected period. Furthermore, the well-established molecular biology industry in developed regions like North America and Europe presents lucrative growth prospects for market expansion. However, high-cost restriction endonucleases production and certain level of unreliability of these enzymes in providing accuracy is expected to stifle market growth between 2022 and 2032.

The key regions considered for the global Restriction Endonucleases Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America was the largest regional market in terms of revenue owing to factors such as the strong presence of industry leaders, substantial investments, and expanding research and development initiatives within the region's biotechnology and pharmaceutical sectors. Restriction enzymes play a key role in scientific research, particularly in genetics research, driving market growth across the region. For instance, data from the NIH's Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC), 2022 update, indicates significant research investment in genetics projects in the United States. Research spending on genetics projects amounted to USD 10,544 million in 2020, USD 11,010 million in 2021, and is estimated to reach USD 11,480 million in 2022. This increasing investment in genetics research in the region is expected to leverage restriction endonucleases for the development of therapies aimed at treating genetic diseases. Moreover, favorable government policies and a rise in collaborative research efforts are anticipated to fuel market expansion further. Whereas, the market in Asia Pacific is expected to grow at the fastest rate over the forecast period.

Major market player included in this report are:

• New England Biolabs
• Agilent Technologies Inc.
• Affymetrix, Inc.
• ThermoFisher Scientific, Inc.
• Promega Corporation
• Genetix Biotech Asia Pvt. Ltd., Inc.
• Takara Bio, Inc.
• Sigma-Aldrich Co. LLC.
• Enzymatics, Inc.
• Illumina, Inc.

The detailed segments and sub-segment of the market are explained below:

By Application

• Polymerase Chain Reaction (PCR)
• Restriction Fragment Length Polymorphism (RFLP)
• Epigenetics
• Restriction Digestion
• Sequencing
• Cloning

By End User

• Hospitals
• Academic Research Institutes
• Pharmaceutical
• Biotechnology Companies
• Diagnostic Centers
• Clinics

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market

Table of Contents

Chapter 1. Global Restriction Endonucleases Market Definition and Research Assumptions

• 1.1. Research Objective
• 1.2. Market Definition
• 1.3. Research Assumptions
  • 1.3.1. Inclusion & Exclusion
  • 1.3.2. Limitations
  • 1.3.3. Supply Side Analysis
    • 1.3.3.1. Availability
    • 1.3.3.2. Infrastructure
    • 1.3.3.3. Regulatory Environment
    • 1.3.3.4. Market Competition
    • 1.3.3.5. Economic Viability (Consumer's Perspective)
  • 1.3.4. Demand Side Analysis
    • 1.3.4.1. Regulatory frameworks
    • 1.3.4.2. Technological Advancements
    • 1.3.4.3. Environmental Considerations
    • 1.3.4.4. Consumer Awareness & Acceptance
• 1.4. Estimation Methodology
• 1.5. Years Considered for the Study
• 1.6. Currency Conversion Rates

Chapter 2. Executive Summary

• 2.1. Global Restriction Endonucleases Market Size & Forecast (2022- 2032)
• 2.2. Regional Summary
• 2.3. Segmental Summary
  • 2.3.1. By Application
  • 2.3.2. By End User
• 2.4. Key Trends
• 2.5. Recession Impact
• 2.6. Analyst Recommendation & Conclusion

Chapter 3. Global Restriction Endonucleases Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Challenges
• 3.3. Market Opportunities

Chapter 4. Global Restriction Endonucleases Market: Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economic
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Restriction Endonucleases Market Size & Forecasts by Application 2022-2032

• 5.1. Polymerase Chain Reaction (PCR)
• 5.2. Restriction Fragment Length Polymorphism (RFLP)
• 5.3. Epigenetics
• 5.4. Restriction Digestion
• 5.5. Sequencing
• 5.6. Cloning

Chapter 6. Global Restriction Endonucleases Market Size & Forecasts by End User 2022-2032

• 6.1. Hospitals
• 6.2. Academic Research Institutes
• 6.3. Pharmaceutical
• 6.4. Biotechnology Companies
• 6.5. Diagnostic Centers
• 6.6. Clinics

Chapter 7. Global Restriction Endonucleases Market Size & Forecasts by Region 2022-2032

• 7.1. North America Restriction Endonucleases Market
  • 7.1.1. U.S. Restriction Endonucleases Market
    • 7.1.1.1. Application breakdown size & forecasts, 2022-2032
    • 7.1.1.2. End User breakdown size & forecasts, 2022-2032
  • 7.1.2. Canada Restriction Endonucleases Market
• 7.2. Europe Restriction Endonucleases Market
  • 7.2.1. U.K. Restriction Endonucleases Market
  • 7.2.2. Germany Restriction Endonucleases Market
  • 7.2.3. France Restriction Endonucleases Market
  • 7.2.4. Spain Restriction Endonucleases Market
  • 7.2.5. Italy Restriction Endonucleases Market
  • 7.2.6. Rest of Europe Restriction Endonucleases Market
• 7.3. Asia-Pacific Restriction Endonucleases Market
  • 7.3.1. China Restriction Endonucleases Market
  • 7.3.2. India Restriction Endonucleases Market
  • 7.3.3. Japan Restriction Endonucleases Market
  • 7.3.4. Australia Restriction Endonucleases Market
  • 7.3.5. South Korea Restriction Endonucleases Market
  • 7.3.6. Rest of Asia Pacific Restriction Endonucleases Market
• 7.4. Latin America Restriction Endonucleases Market
  • 7.4.1. Brazil Restriction Endonucleases Market
  • 7.4.2. Mexico Restriction Endonucleases Market
  • 7.4.3. Rest of Latin America Restriction Endonucleases Market
• 7.5. Middle East & Africa Restriction Endonucleases Market
  • 7.5.1. Saudi Arabia Restriction Endonucleases Market
  • 7.5.2. South Africa Restriction Endonucleases Market
  • 7.5.3. Rest of Middle East & Africa Restriction Endonucleases Market

Chapter 8. Competitive Intelligence

• 8.1. Key Company SWOT Analysis
• 8.2. Top Market Strategies
• 8.3. Company Profiles
  • 8.3.1. New England Biolabs
    • 8.3.1.1. Key Information
    • 8.3.1.2. Overview
    • 8.3.1.3. Financial (Subject to Data Availability)
    • 8.3.1.4. Product Summary
    • 8.3.1.5. Market Strategies
  • 8.3.2. Agilent Technologies, Inc.
  • 8.3.3. Affymetrix, Inc.
  • 8.3.4. ThermoFisher Scientific, Inc.
  • 8.3.5. Promega Corporation
  • 8.3.6. Genetix Biotech Asia Pvt. Ltd., Inc.
  • 8.3.7. Takara Bio, Inc.
  • 8.3.8. Sigma-Aldrich Co. LLC.
  • 8.3.9. Enzymatics, Inc.
  • 8.3.10. Illumina, Inc.

Chapter 9. Research Process

• 9.1. Research Process
  • 9.1.1. Data Mining
  • 9.1.2. Analysis
  • 9.1.3. Market Estimation
  • 9.1.4. Validation
  • 9.1.5. Publishing
• 9.2. Research Attributes